Rocketvax AG selected to participate in SIX Swiss Exchange Sparks IPO Academy
Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members
Swiss Rockets AG further advances its technologies in cooperation with Serbia
Nasal vaccine against coronavirus further improved
New vaccine concept against SARS-CoV-2 successfully tested
Torqur AG's cancer drug candidate bimiralisib with promising new study results
Swiss Rockets AG Welcomes Three New Key Members To The Team
RocketVax Nasal Vaccine to Prevent COVID-19 Passes First Tests
CNN Health Reports About RocketVax Covid-19 Nasal Vaccine
RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward
Swiss Rockets further strengthens the development of its phase II cancer drug candidate bimiralisib
RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines
Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award
Burkhard Frey joins Swiss Rockets AG as Chief Commercial Officer
Dr. Milan Crnogorac joins Swiss Rockets AG as Chief Technology Officer
